GLP -1 agonists Injections -

World adult obesity prevalence 15 %

USA adult obesity prevalence   44 %

One of the side effect of GLP 1 agonists is loss of appetite, which in turn can lead to weight loss.

This has been marketed to Gen Z, mobile surfers couch potato obese people as magic recipe. 

Two companies hold 98 % of the current market share of these injections.

Their FY 23, revenue was 24 + 12 billion USD. 

Looks like, simple solutions of monitoring the quality & quantity of food intake &
Exercise is out of fashion.